Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals (IONS) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The press release (Exhibit 99.1) presents both GAAP and non-GAAP figures. Non-GAAP results exclude non-cash compensation expense related to equity awards and the related tax effects, which the company says helps users assess and compare performance and project future results and cash flows. The information and exhibit are furnished under Item 2.02 and are not deemed filed under Section 18 of the Exchange Act.
Ionis Pharmaceuticals (IONS) reported insider transactions by EVP Research Eric Swayze on a Form 4. On 10/15/2025, 125 shares of common stock were acquired at $0.00 upon vesting of a Restricted Stock Unit award, held indirectly by his son. On 10/16/2025, 53 shares were sold at $73.6213 pursuant to an automatic sale to cover required tax withholding.
Following these transactions, 256 shares were indirectly held by his son and 30,453 shares were held directly. Derivative holdings included 497 Restricted Stock Units indirectly held.
Ionis Pharmaceuticals (IONS) disclosed insider transactions by EVP, Corp and Development Ops Brian Birchler. On 10/14/2025 and 10/15/2025, he exercised non-qualified stock options at $53.77 for 11,475 and 12,425 shares (codes M) and sold the same amounts at weighted average prices of $72.0339 and $72.2252 (codes S) pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. After these trades, he directly owned 56,826 shares.
Ionis Pharmaceuticals (IONS) — Form 4: EVP and Chief Human Resources Officer Shannon L. Devers exercised options for 6,000 shares at $48.51 on 10/15/2025, then sold 6,000 shares the same day at a weighted average price of $72.9423 pursuant to a Rule 10b5-1 trading plan adopted on September 3, 2024. Also on 10/15/2025, 2,820 shares were acquired upon RSU vesting at no cost, and on 10/16/2025, 1,263 shares were sold at $73.6213 to cover tax withholding.
Following these transactions, Devers directly owned 17,494 shares of common stock. RSUs vest in four equal annual installments; each RSU represents a right to one share or its cash equivalent. The stock option exercised was originally granted on 04/05/2021 and expires on 04/04/2027.
Ionis Pharmaceuticals (IONS) director B. Lynne Parshall reported a sale of common stock. On 10/15/2025, the reporting person sold 5,000 shares of Ionis common stock at a weighted average price of $71.7443, with individual trade prices ranging from $71.265 to $72.06.
The transaction was conducted under a Rule 10b5-1 trading plan adopted on May 6, 2025. Following the sale, the reporting person beneficially owns 61,344 shares, held directly.
Officer sale under 10b5-1 plan reduced direct holdings. An executive, Eric Swayze, reported the sale of 6,849 shares of Ionis Pharmaceuticals common stock on 10/06/2025 at a weighted-average price of $69.02. The filing states these sales were executed pursuant to a Rule 10b5-1 trading plan adopted on 08/14/2024, meaning they were pre-arranged instructions rather than discretionary trades.
After the transactions, the reporting person beneficially owns 30,453 shares directly and an additional 184 shares indirectly through a family member. The filer offers to provide detailed per-trade price information to the company, shareholders, or the SEC on request.
Ionis Pharmaceuticals executive vice president, CLO & General Counsel Patrick R. O'Neil exercised 10,200 non-qualified stock options on October 6, 2025 at a strike price of $52.8700 per share, acquiring common stock. He then sold 13,441 shares at weighted-average prices of $69.8872 and $69.2651 pursuant to a Rule 10b5-1 trading plan adopted on May 2, 2025. After these transactions, he directly holds 53,889 Ionis common shares and 17,000 options from this grant, which are exercisable from January 2, 2025 and expire on January 1, 2034.
Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported a sale of common stock under a pre-established Rule 10b5-1 trading plan. The report shows 437 shares were sold on 10/06/2025 at $69.2637 per share, leaving the reporting person with 179,572 shares beneficially owned after the transaction. The filing notes the 10b5-1 plan was adopted on 08/13/2024 and the Form 4 was signed via attorney-in-fact on 10/08/2025. The transaction is described as executed pursuant to the trading plan.
Insider sale under 10b5-1 plan. An officer of Ionis Pharmaceuticals (IONS), Joseph T. Baroldi, sold 1,625 shares of common stock on 10/06/2025 at a weighted-average price of $69.3693 per share under a Rule 10b5-1 trading plan adopted on 05/02/2025. After the reported sale, Mr. Baroldi directly beneficially owns 30,301 shares and indirectly owns 3,071 shares through his spouse. The filer notes the sale occurred in multiple transactions at prices ranging from $69.36 to $69.41 and offers to provide a price-by-price breakdown on request.
Insider notice to sell common stock: A Form 144 filing shows proposed sale of 437 shares of common stock on 10/06/2025 via Stifel Nicolaus & Company on Nasdaq with an aggregate market value of $30,268.00. The shares were acquired under an Employee Stock Purchase Plan on 09/03/2024 and paid in cash. The filer represents no undisclosed material adverse information and the filing includes prior sales by the same person totaling 208,648 shares across dates in 2025 with gross proceeds shown (largest single prior sale: $12,228,840.00 on 09/03/2025). The notice states standard Rule 144 and Rule 10b5-1 remarks and signature attestation.